Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?

被引：0
|
作者：
Renguo Guan
Jie Mei
Wenping Lin
Min Deng
Shaohua Li
Rongping Guo
机构：
[1] Sun Yat-sen University Cancer Center,Department of Hepatobiliary Oncology
[2] State Key Laboratory of Oncology in South China,undefined
[3] Collaborative Innovation Center for Cancer Medicine,undefined
来源：
Hepatology International | 2023年 / 17卷
关键词：
Hepatocellular carcinoma; Programmed cell death 1; Hepatic arterial infusion chemotherapy; Transhepatic arterial chemotherapy and embolization; C‑reactive protein; Alpha‑fetoprotein; C‑reactive protein and alpha‑fetoprotein in immunotherapy score; Adverse events; Overall survival; Progression-free survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1279 / 1288
页数：9
相关论文
共 50 条
  • [21] Association of immune related adverse events with superior outcomes in patients with hepatocellular carcinoma (HCC) treated with nivolumab.
    Ostios-Garcia, Lorena
    Ramiro-Cortijo, David
    Peters, Mary Linton Bounetheau
    Bullock, Andrea J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
    Soria, Anna
    Calvo, Mariona
    Casas, Meritxell
    Vidales, Zara
    Munoz-Martinez, Sergio
    Sapena, Victor
    Puigvehi, Marc
    Canillas, Lidia
    Guardeno, Raquel
    Gallego, Adolfo
    Minguez, Beatriz
    Horta, Diana
    Clos, Ariadna
    Montoliu, Silvia
    Roget, Merce
    Reig, Maria
    Vergara, Mercedes
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [23] Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib
    Granito, Alessandro
    Marinelli, Sara
    Negrini, Giulia
    Menetti, Saverio
    Benevento, Francesca
    Bolondi, Luigi
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (02): : 240 - 249
  • [24] Cuproptosis-related genes score: A predictor for hepatocellular carcinoma prognosis, immunotherapy efficacy, and metabolic reprogramming
    Nie, Guilin
    Peng, Dingzhong
    Wen, Ningyuan
    Wang, Yaoqun
    Lu, Jiong
    Li, Bei
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [25] Systematic review and metanalysis establish dermatologic adverse events as a positive predictor of survival in hepatocellular carcinoma patients treated with sorafenib
    Diaz-Gonzalez, A.
    Sanduzzi-Zamparelli, M.
    Sapena, V.
    Torres, F.
    Llarch, N.
    Iserte, G.
    Forner, A.
    Da Fonseca, L. G.
    Rios, J.
    Bruix, J.
    Reig, M.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S195 - S195
  • [26] Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors
    Xu, Shuo
    Lai, Ruixue
    Zhao, Qian
    Zhao, Pandong
    Zhao, Ruili
    Guo, Zhanjun
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [27] Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
    Shimose, Shigeo
    Iwamoto, Hideki
    Tanaka, Masatoshi
    Niizeki, Takashi
    Kajiwara, Masahiko
    Itano, Satoshi
    Moriyama, Etsuko
    Shirono, Tomotake
    Noda, Yu
    Kamachi, Naoki
    Nakano, Masahito
    Kuromatsu, Ryoko
    Koga, Hironori
    Kawaguchi, Takumi
    CANCERS, 2022, 14 (17)
  • [28] Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy
    Guo, De-Zhen
    Zhang, Shi-Yu
    Dong, San-Yuan
    Yan, Jia-Yan
    Wang, Yu-Peng
    Cao, Ya
    Rao, Sheng-Xiang
    Fan, Jia
    Yang, Xin-Rong
    Huang, Ao
    Zhou, Jian
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
    Gong, B.
    Lu, L.
    Yang, H.
    Xiong, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1552 - S1552
  • [30] The CRAFITY score emerges as a paramount prognostic indicator in hepatocellular carcinoma patients received Lenvatinib and Pembrolizumab
    Wu, Weijie
    Yang, Zhenyun
    Zou, Hao
    Long, Teng
    Zhou, Zhongguo
    Zhang, Yaojun
    Chen, Minshan
    Hu, Dandan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
12345